List of Excipients in Branded Drug TESTOSTERONE ENANTHATE

Generic Drugs Containing TESTOSTERONE ENANTHATE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	testosterone enanthate	0143-9750	CHLOROBUTANOL
Hikma Pharmaceuticals USA Inc	testosterone enanthate	0143-9750	SESAME OIL
Eugia US LLC	testosterone enanthate	55150-336	CHLOROBUTANOL
Eugia US LLC	testosterone enanthate	55150-336	SESAME OIL

What are the Most Frequently-Used Excipients in TESTOSTERONE ENANTHATE?

# Of NDCs	Excipient
2	CHLOROBUTANOL
2	SESAME OIL

Testosterone enanthate has limited active-ingredient exclusivity but meaningful commercial opportunity in delivery systems, excipient selection, preservative strategy, and patient-convenience products. The strongest opportunity is a differentiated subcutaneous or self-administered formulation that improves injection tolerability, reduces viscosity, and supports stable room-temperature storage. Xyosted established the commercial value of an auto-injector presentation, while conventional intramuscular products remain exposed to generic competition.

Last updated: August 21, 2026

Testosterone Enanthate Excipient Strategy and Commercial Opportunities

What is the commercial market for testosterone enanthate?

Testosterone enanthate is a long-acting ester prodrug of testosterone used for testosterone replacement therapy in males with confirmed hypogonadism. It is administered primarily by intramuscular injection, while Xyosted provides a subcutaneous, single-dose autoinjector presentation.

The market divides into four product categories:

Product category	Typical route	Commercial position	Main differentiation
Conventional testosterone enanthate injection	Intramuscular	Generic and branded	Price, supply reliability, concentration
Xyosted	Subcutaneous	Branded prescription product	Autoinjector, home administration, weekly dosing
Compounded testosterone enanthate	Intramuscular or subcutaneous	Low-cost channel	Custom concentrations and packaging
Next-generation enanthate products	Subcutaneous, depot, implant, or wearable delivery	Development opportunity	Lower injection burden, improved tolerability, adherence

Xyosted contains testosterone enanthate at 50 mg, 75 mg, or 100 mg per 0.5 mL and is administered once weekly by subcutaneous injection. The product uses a prefilled autoinjector rather than a conventional vial and syringe [1].

Conventional testosterone enanthate products are commonly supplied at 200 mg/mL for intramuscular administration. Delatestryl, a historical branded reference product, used an oil-based injection format and had substantially different excipient and preservative requirements from Xyosted [2].

What excipients are used in testosterone enanthate products?

The main excipient platforms are sesame oil, benzyl benzoate, benzyl alcohol, chlorobutanol, and other injectable oil vehicles. The precise composition depends on concentration, route, container closure, preservative strategy, and intended shelf life.

Xyosted excipient profile

The Xyosted formulation uses sesame oil and benzyl benzoate as inactive ingredients, with testosterone enanthate dissolved in an oil vehicle for subcutaneous delivery [1]. Its commercial formulation is designed around a low-volume 0.5 mL dose and administration through an autoinjector.

The formulation objectives are:

• Maintain testosterone enanthate solubility at relatively high drug concentration.
• Limit injection volume.
• Permit subcutaneous administration.
• Support consistent delivery through a narrow-gauge needle.
• Maintain compatibility with the autoinjector, syringe, needle, and elastomeric components.
• Avoid the need for patient-drawn doses and multidose-vial preservatives.

Conventional intramuscular formulations

Conventional testosterone enanthate injections use oil vehicles such as sesame oil or cottonseed oil. Depending on the product, benzyl alcohol or chlorobutanol may be used as a preservative. These formulations generally tolerate higher injection volumes than subcutaneous products but can create greater pain, leakage, local swelling, and patient resistance to self-administration [2,3].

The excipient decision is not interchangeable across routes. An oil vehicle acceptable for a deep intramuscular injection may be poorly suited to a subcutaneous product because of local tolerability, depot persistence, viscosity, or injection force.

Which excipients offer the strongest formulation opportunities?

The most commercially relevant excipient opportunities involve vehicle substitution, viscosity reduction, preservative elimination, and local-tolerability improvement.

Sesame oil

Sesame oil is widely used in injectable testosterone esters because it dissolves lipophilic drug substances and supports depot formation. Its limitations include:

• Potential sensitivity or allergy concerns.
• Batch-to-batch variability in natural-source materials.
• Oxidative degradation risk.
• Possible high viscosity at concentrated drug loads.
• Supply-chain qualification requirements.

A synthetic or highly controlled alternative oil could support a differentiated product if it improves oxidation stability, injection force, or patient tolerability.

Cottonseed oil

Cottonseed oil has a long history in depot injections and may support testosterone enanthate solubilization. It can be commercially attractive where supply is established, but it creates similar concerns involving natural-source variability, impurities, oxidation, and patient-specific sensitivity.

A switch from sesame oil to cottonseed oil would not automatically create clinical differentiation. The commercial value would depend on demonstrable improvements in injection comfort, stability, manufacturing consistency, or allergy management.

Benzyl benzoate

Benzyl benzoate can act as a co-solvent and improve testosterone enanthate solubility. It may permit a lower-viscosity formulation or higher drug concentration. Its use requires careful control of local tolerability and systemic exposure.

A benzyl benzoate strategy is most valuable when it enables:

• A smaller injection volume.
• A higher concentration.
• Lower injection force.
• A more robust cold-chain or room-temperature profile.
• Improved compatibility with an autoinjector.

The risk is that increasing co-solvent content may worsen injection-site reactions or create regulatory questions about tolerability in chronic use.

Benzyl alcohol

Benzyl alcohol is used as a preservative in some multidose injectable products. It can support repeated vial access and microbial control, but its value is lower in single-dose presentations.

A preservative-free formulation is commercially preferable when the product is supplied as a single-use prefilled syringe or autoinjector. Removing benzyl alcohol can reduce excipient exposure and simplify a chronic-use safety narrative, although the container closure and manufacturing process must provide adequate sterility assurance.

Chlorobutanol

Chlorobutanol has been used in some oil-based injectable products as a preservative. Its commercial relevance is strongest in older multidose vial formats. It is less attractive for modern self-administration products, where single-dose packaging can remove the need for a preservative.

How does route of administration affect excipient strategy?

Route is the principal formulation constraint.

Attribute	Intramuscular testosterone enanthate	Subcutaneous testosterone enanthate
Acceptable injection volume	Higher	Lower
Needle size	Often larger	Smaller
Vehicle viscosity tolerance	Higher	Lower
Local depot burden	More acceptable	More sensitive
Self-administration	Less convenient	More suitable
Device dependence	Low	High
Preservative requirement	More likely in multidose vials	Lower in single-dose systems
Differentiation potential	Limited	High

An intramuscular product can compete on price, concentration, vial size, and availability. A subcutaneous product can compete on adherence, convenience, injection frequency, device design, and patient experience.

For a new subcutaneous formulation, the critical target is not simply maximum testosterone concentration. The formulation must balance solubility, viscosity, injection force, depot behavior, local tolerability, and dose accuracy.

What formulations are protected by testosterone enanthate patents?

The active pharmaceutical ingredient itself has no meaningful new-molecule exclusivity. Commercial protection is more likely to arise from:

• Subcutaneous administration methods.
• Specific dose ranges and weekly dosing regimens.
• Testosterone enanthate concentrations.
• Oil and co-solvent combinations.
• Prefilled syringe or autoinjector systems.
• Needle geometry and injection-force control.
• Formulation stability.
• Patient-selection or titration methods.
• Combination of formulation and delivery device.

Xyosted was approved by the FDA in 2018 under NDA 208088. Its regulatory differentiation rests on the combination of testosterone enanthate, subcutaneous administration, fixed-volume dosing, and an autoinjector presentation [1,4].

Orange Book and patent expiration

The FDA Orange Book is the controlling source for listed patents, patent-use codes, and regulatory exclusivity associated with an approved drug product [5]. Xyosted’s commercial protection must be evaluated at the product level rather than by asking whether testosterone enanthate as a molecule remains patented.

The relevant diligence questions are:

1. Which Xyosted patents remain listed in the Orange Book?
2. Which claims cover the formulation rather than only the device?
3. Which method-of-use claims have corresponding patent-use codes?
4. Are any listed patents vulnerable to an abbreviated new drug application challenge?
5. Does a competing product require a Paragraph IV certification?
6. Can a generic design around the autoinjector and pursue a different dosage form?

A generic testosterone enanthate injection does not necessarily threaten all Xyosted sales. An intramuscular vial may be therapeutically substitutable in some patients but is not the same commercial product as a weekly subcutaneous autoinjector.

When does testosterone enanthate lose exclusivity?

Conventional testosterone enanthate injection is already exposed to generic competition in the United States. The important exclusivity question concerns the product presentation, not the ester alone.

For Xyosted, market entry depends on the remaining Orange Book patent estate, any regulatory exclusivity, the ANDA applicant’s certification strategy, and whether the applicant seeks approval for an equivalent autoinjector or a legally distinct presentation.

Generic entry scenarios

Scenario	Likely impact
Generic intramuscular vial	Price pressure on conventional injections; limited direct impact on Xyosted
Generic subcutaneous vial or syringe	Greater pressure on Xyosted if substitutable and clinically accepted
Generic autoinjector	Highest direct threat to Xyosted
Compounded subcutaneous product	May erode cash-pay and convenience segments but lacks full FDA approval
New branded low-viscosity formulation	Could compete without being therapeutically identical
Long-acting implant or depot	May reduce weekly injection demand in selected patients

A Paragraph IV challenge would be commercially significant if it targets an Orange Book-listed Xyosted patent and triggers the statutory litigation framework. A successful challenge could produce earlier entry; a settlement could establish a negotiated launch date and restrictions on the competing product’s formulation or device.

Which companies are challenging testosterone enanthate exclusivity?

The competitive field includes generic injectable manufacturers, specialty hormone-therapy companies, compounding pharmacies, and developers of alternative testosterone delivery systems.

Generic competition is concentrated in conventional testosterone enanthate injection. Companies with broad sterile-injectable capabilities can compete on:

• 200 mg/mL vial supply.
• Contract manufacturing.
• Hospital and clinic distribution.
• Wholesale acquisition price.
• Shortage resilience.
• Packaging configurations.

The Xyosted opportunity is more difficult because a challenger must address the device, subcutaneous route, dose presentation, and regulatory equivalence strategy. A product can compete commercially without being an ANDA-equivalent product, but it may require a separate 505(b)(2) or NDA pathway depending on the formulation and delivery changes [6].

What FDA regulatory pathway applies to a new testosterone enanthate product?

The pathway depends on the proposed product.

ANDA pathway

An ANDA is most suitable for a product that matches the reference product in active ingredient, dosage form, route, strength, quality attributes, and bioequivalence requirements. The applicant must also address device requirements if the reference product uses a combination product presentation [6].

An ANDA strategy is strongest for conventional testosterone enanthate injection where the reference product and generic product have established pharmaceutical equivalence criteria.

505(b)(2) pathway

A 505(b)(2) application is more suitable for:

• A different oil vehicle.
• A new concentration.
• A subcutaneous product based on an intramuscular reference.
• A new injection device.
• A new dosing schedule.
• A formulation with a new preservative strategy.
• A prefilled or autoinjector presentation with clinical bridging.

The pathway may reduce the need to repeat the full clinical development program, but the sponsor still must address pharmacokinetics, local tolerability, dose titration, device performance, and chronic-use safety.

Combination-product requirements

An autoinjector product requires integrated development of:

• Drug formulation.
• Primary container.
• Needle.
• Delivery mechanism.
• Human factors.
• Extractables and leachables.
• Injection-force profile.
• Dose completeness.
• Shipping and temperature robustness.

The device can create both regulatory complexity and patent value.

How strong is the patent estate for testosterone enanthate products?

The patent estate is weak for the old injectable molecule and stronger for differentiated delivery.

Lower-value claim areas

• Testosterone enanthate as a known ester.
• Conventional sesame-oil injection.
• Standard 200 mg/mL intramuscular vial.
• Basic preservative-containing multidose packaging.

These areas are generally vulnerable to generic competition and design-around strategies.

Higher-value claim areas

• Low-volume subcutaneous delivery.
• Specific concentration and viscosity limits.
• Weekly dose titration.
• Autoinjector configuration.
• Formulation-device integration.
• Improved injection-force performance.
• Reduced injection-site pain.
• Preservative-free single-dose packaging.
• Stability under room-temperature storage.

A commercially strong estate should combine composition claims, method-of-use claims, and device claims. Composition-only protection may be easier to design around through vehicle substitution. Device-only protection may leave the underlying drug formulation exposed. Method claims can protect dosing practices but may be narrower in enforcement and depend on prescribing and labeling behavior.

What manufacturing and intellectual-property barriers exist?

Manufacturing barriers are moderate for conventional vials and higher for self-injecting combination products.

The principal barriers are:

• Sterile compounding and aseptic filling.
• Control of oil oxidation.
• Consistent testosterone enanthate assay and impurities.
• High-viscosity filling.
• Container closure compatibility.
• Autoinjector force and dose accuracy.
• Extractables and leachables.
• Device assembly yield.
• Stability testing in the final marketed configuration.
• Human-factors validation.

A new excipient system can create manufacturing value if it increases drug loading or reduces filling force without increasing degradation. It can also create IP value through narrow but defensible composition ranges tied to performance data.

What licensing opportunities exist in testosterone enanthate?

The most attractive licensing assets are enabling technologies rather than the testosterone enanthate molecule.

Potential licensing targets include:

• Low-viscosity injectable oil systems.
• Synthetic lipid vehicles.
• Preservative-free multidose technologies.
• Autoinjectors for viscous formulations.
• Microneedle or wearable delivery systems.
• Depot-forming excipient platforms.
• Oxidation-control packages.
• Prefilled syringe systems.
• Manufacturing processes that reduce particulate formation.
• Digital adherence and dose-titration tools.

A formulation licensor can create value through a platform license covering multiple testosterone esters or other lipophilic injectables. The strongest deal structure would link royalties to approved product milestones, commercial sales, or successful patent-term extension rather than relying solely on upfront payments.

How does testosterone enanthate compare with testosterone undecanoate?

Testosterone enanthate and testosterone undecanoate compete in testosterone replacement therapy but have different formulation and commercial profiles.

Attribute	Testosterone enanthate	Testosterone undecanoate
Common U.S. injection formats	Intramuscular and subcutaneous	Long-acting intramuscular
Dosing interval	Often weekly or every 1-2 weeks	Much less frequent
Excipient challenge	Solubility, viscosity, local tolerability	Large depot volume and administration logistics
Self-administration potential	Higher	Lower
Device opportunity	High	Moderate
Generic exposure	High for conventional injection	More limited for certain branded presentations
Main commercial advantage	Flexible dosing and home use	Reduced injection frequency

Enanthate is better suited to a convenience-focused self-administration strategy. Undecanoate has a stronger long-acting value proposition but faces greater constraints from large injection volume, clinical administration, and safety monitoring requirements.

What revenue exposure and commercial opportunities exist?

Revenue exposure is highest for products that depend on premium pricing over generic testosterone enanthate injection. A conventional vial business is vulnerable to price compression and channel substitution. A branded autoinjector can preserve pricing if it demonstrates a measurable benefit in adherence, persistence, patient preference, or reduced administration burden.

Commercial opportunities include:

1. A low-cost generic 200 mg/mL injection with reliable supply.
2. A preservative-free single-dose vial or prefilled syringe.
3. A lower-viscosity subcutaneous formulation.
4. A 0.5 mL or smaller-volume autoinjector.
5. A formulation designed for reduced injection-site pain.
6. A room-temperature-stable product for specialty pharmacy distribution.
7. A product with integrated dose titration and adherence support.
8. A formulation platform applicable to testosterone cypionate and other lipophilic esters.

The largest defensible premium is likely to come from delivery convenience rather than a new excipient alone. Excipients should support a clinically visible product benefit and a patentable formulation or device configuration.

What is the outlook for biosimilar and generic risk?

Biosimilar risk is not relevant because testosterone enanthate is a synthetic small-molecule drug, not a biologic. The relevant competitive risks are generic injectable products, 505(b)(2) reformulations, branded alternative testosterone products, and compounded formulations.

Generic risk is high for standard intramuscular vials. It is lower for a differentiated subcutaneous autoinjector when the product has device, formulation, and method-of-use protection. That protection weakens if a competitor can offer a clinically acceptable prefilled syringe or vial with materially lower cost.

Key Takeaways

• Testosterone enanthate has limited active-ingredient exclusivity and substantial generic exposure in conventional intramuscular injections.
• The strongest commercial opportunity is a subcutaneous, low-volume, self-administered product.
• Sesame oil, cottonseed oil, benzyl benzoate, benzyl alcohol, and chlorobutanol are the principal excipient tools in existing formulations.
• Preservative-free single-dose packaging is more attractive than preserved multidose vials for premium products.
• A new vehicle is commercially valuable only if it improves solubility, viscosity, injection force, tolerability, stability, or device performance.
• Xyosted demonstrates the value of combining testosterone enanthate with an autoinjector and weekly subcutaneous dosing.
• Patent strength is highest where formulation, device, dosing method, and performance claims overlap.
• Conventional generic testosterone enanthate is a high-price-pressure market; differentiated delivery remains the higher-value segment.
• Biosimilar competition does not apply. Generic, 505(b)(2), branded, and compounded competition does.
• Licensing value is concentrated in injectable excipient platforms, device technologies, and manufacturing processes rather than in testosterone enanthate itself.

FAQs

Can testosterone enanthate be formulated without sesame oil?

Yes. Alternative vehicles such as cottonseed oil or synthetic lipid systems may be feasible, but the replacement must maintain solubility, stability, sterility, injection performance, and local tolerability.

Is benzyl alcohol necessary in a testosterone enanthate injection?

No. It is more relevant to multidose vial preservation. A single-dose prefilled syringe or autoinjector may support a preservative-free design.

Can a generic company avoid Xyosted patents by using a vial?

Potentially. A vial-based product may avoid device claims, but it could still implicate formulation, route-of-administration, dosage, or method-of-use claims listed for the reference product.

What is the best excipient strategy for a weekly subcutaneous product?

The preferred strategy is a low-viscosity, oxidation-controlled oil system that maintains testosterone enanthate solubility in a small volume and minimizes injection-site reactions.

Does testosterone enanthate have an opportunity in wearable delivery?

Yes. Wearable or microneedle delivery could reduce injection burden, but the formulation must address depot formation, dose delivery, device residence time, skin tolerability, and manufacturing complexity.

References

1. U.S. Food and Drug Administration. (2023). Xyosted (testosterone enanthate) injection, for subcutaneous use: Prescribing information.
2. Endo Pharmaceuticals Inc. (2020). Delatestryl (testosterone enanthate injection, USP) prescribing information.
3. U.S. Food and Drug Administration. (2023). Testosterone enanthate injection, USP: Product labeling and inactive ingredients.
4. U.S. Food and Drug Administration. (2018). FDA approves new testosterone replacement therapy product, Xyosted.
5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
6. U.S. Food and Drug Administration. (2024). Applications covered by section 505(b)(2).